Unknown

Dataset Information

0

? Opioids inhibit tumor angiogenesis by suppressing VEGF signaling.

ABSTRACT: Opioids are effective analgesics for the management of moderate to severe cancer pain. Here we show that ? opioid receptor (KOR) agonists act as anti-angiogenic factors in tumors. Treatment with KOR agonists, U50,488H and TRK820, significantly inhibited human umbilical vein endothelial cell (HUVEC) migration and tube formation by suppressing VEGFR2 expression. In contrast, treatment with a ? opioid receptor agonist, DAMGO, or a ? opioid receptor agonist, SNC80, did not prevent angiogenesis in HUVECs. Lewis lung carcinoma (LLC) or B16 melanoma grafted in KOR knockout mice showed increased proliferation and remarkably enhanced tumor angiogenesis compared with those in wild type mice. On the other hand, repeated intraperitoneal injection of TRK820 (0.1-10 ?g/kg, b.i.d.) significantly inhibited tumor growth by suppressing tumor angiogenesis. These findings indicate that KOR agonists play an important role in tumor angiogenesis and this knowledge could lead to a novel strategy for cancer therapy.

SUBMITTER: Yamamizu K 

PROVIDER: S-EPMC3827603 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Opioids are effective analgesics for the management of moderate to severe cancer pain. Here we show that κ opioid receptor (KOR) agonists act as anti-angiogenic factors in tumors. Treatment with KOR agonists, U50,488H and TRK820, significantly inhibited human umbilical vein endothelial cell (HUVEC) migration and tube formation by suppressing VEGFR2 expression. In contrast, treatment with a μ opioid receptor agonist, DAMGO, or a δ opioid receptor agonist, SNC80, did not prevent angiogenesis in HU  ...[more]

Similar Datasets

Unknown L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
| S-EPMC3248743 | biostudies-literature
Unknown Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
| S-EPMC5347735 | biostudies-literature
Unknown Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling.
| S-EPMC5129999 | biostudies-literature
Unknown Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
| S-EPMC4823125 | biostudies-literature
Unknown CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.
| S-EPMC1986788 | biostudies-literature
Unknown Atypical E2Fs inhibit tumor angiogenesis.
| S-EPMC5770600 | biostudies-literature
Unknown Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function.
| S-EPMC9496920 | biostudies-literature
Unknown Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
| S-EPMC5355302 | biostudies-literature
Unknown Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells.
| S-EPMC3111273 | biostudies-literature
Unknown Tissue deformation spatially modulates VEGF signaling and angiogenesis.
| S-EPMC3344996 | biostudies-literature